Equities Analysts Offer Predictions for Sophiris Bio Inc’s Q3 2016 Earnings (SPHS)
Sophiris Bio Inc (NASDAQ:SPHS) – Investment analysts at Roth Capital issued their Q3 2016 earnings estimates for shares of Sophiris Bio in a note issued to investors on Wednesday. Roth Capital analyst J. Pantginis forecasts that the brokerage will post earnings per share of ($0.07) for the quarter. Roth Capital currently has a “Buy” rating and a $8.00 target price on the stock. Roth Capital also issued estimates for Sophiris Bio’s Q4 2016 earnings at ($0.06) EPS, FY2016 earnings at ($0.33) EPS, FY2017 earnings at ($0.38) EPS, FY2018 earnings at ($0.41) EPS, FY2019 earnings at ($0.48) EPS and FY2020 earnings at ($0.23) EPS.
Several other research firms have also issued reports on SPHS. Maxim Group lifted their price target on shares of Sophiris Bio from $4.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, August 10th. Piper Jaffray Cos. initiated coverage on shares of Sophiris Bio in a report on Tuesday, August 30th. They issued an “overweight” rating and a $7.00 price target on the stock. Finally, Echelon Wealth Partners reaffirmed a “buy” rating and issued a $5.00 price target on shares of Sophiris Bio in a report on Friday, June 10th.
Shares of Sophiris Bio (NASDAQ:SPHS) opened at 2.90 on Monday. The stock’s market cap is $65.59 million. Sophiris Bio has a 52 week low of $0.67 and a 52 week high of $8.55. The firm has a 50-day moving average price of $4.04 and a 200-day moving average price of $2.42.
An institutional investor recently raised its position in Sophiris Bio stock. Citadel Advisors LLC increased its stake in Sophiris Bio Inc (NASDAQ:SPHS) by 65.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,176 shares of the biopharmaceutical company’s stock after buying an additional 19,402 shares during the period. Citadel Advisors LLC owned about 0.23% of Sophiris Bio worth $106,000 as of its most recent SEC filing. Institutional investors and hedge funds own 5.29% of the company’s stock.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.